KRAS testing officially recommended for colon cancer
Executive Summary
The American Society of Clinical Oncology is the first to officially release a clinical opinion that patients with metastatic colorectal cancer who are candidates for anti-EGFR therapy should have their tumors tested for KRAS gene mutations. Patients with mutated forms of the KRAS gene should not use anti-EGFR therapy, based on recent studies indicating that the treatment is only effective in patient with the wild-type form of the KRAS gene, the opinion states. While many in industry and government and non-government health care have touted the benefit of tumor testing, the society's Provisional Clinical Opinion, published in the Journal of Clinical Oncology, is the first to directly recommend it. It is estimated that 40 percent of patients with colon cancer have the KRAS mutation. The opinion was first made public at the American Gastrointestinal Association in January, where another study was presented showing that routine KRAS testing could save the U.S. health care system up to $604 million
You may also be interested in...
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.